MBX Biosciences, Inc.
Carmel, Indiana, United States · Biopharma, Biotechnology, Healthcare
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company pioneering Precision Endocrine Peptide™ (PEP™) therapeutic candidates to help people with endocrine disorders live fuller and healthier lives. The company is advancing a pipeline of PEPs for clinically validated targets designed to deliver superior pharmaceutical properties and overcome key limitations of native peptide therapeuti
Key facts
- Headquarters
- Carmel, Indiana, United States
- Employees
- Unknown
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Public (MBX)
- Website
- mbxbio.com
- Company page
Recent activity at MBX Biosciences, Inc.
- : MBX Biosciences Appoints Karen Basbaum as Chief Business Officer
- : SEC 8-K (5.02): On October 20, 2026, MBX Biosciences, Inc. appointed Peter Radovich as a director of the Company, following recommendations from the Nominating and Corporate Governance Committee. Radovich is categorized as an independent director under Nasdaq standards and will serve as a Class I director until the 2028 Annual Meeting of Stockholders. As part of his appointment, he will receive a non-qualified stock option to purchase 18,200 shares of common stock and additional cash compensation per the Company's Director Compensation Policy. The Board's decision also increased its size to eight directors, and an indemnification agreement will be established for Radovich, mirroring those of other directors without any conflicts or transactions requiring disclosure.
- : SEC 8-K (7.01): On August 27, 2026, MBX Biosciences, Inc. announced the dosing of the first patient in its pivotal Phase 3 oPTimize trial evaluating Once-Weekly Canvuparatide for adults with Hypoparathyroidism. This significant milestone highlights the advancement of the Company's clinical development for Canvuparatide, aimed at addressing unmet needs in managing Hypoparathyroidism. The trial's success could lead to a promising treatment option for patients and impact the Company's market positioning and potential revenue generation. A detailed press release regarding this announcement is attached as Exhibit 99.1 to the filing.
- : SEC 8-K (8.01): On August 6, 2026, MBX Biosciences provided an update regarding its Phase 1 clinical trial for MBX 4291, which involves evaluating a new titration regimen in adult participants with obesity. The trial is structured as a 12-week multiple ascending dose regimen with doses of 30 mg (once-weekly for four weeks) and 120 mg and 180 mg (both once-monthly). The company is projected to report the results from the first cohort in the fourth quarter of 2026. The update outlines continued advancement in their pipeline and underscores potential risks such as regulatory approvals, execution of clinical trials, and financial conditions that could affect the company's operations and stock value.
- : SEC 8-K (5.02): Dr. Kent P. Hawryluk has departed from his position as Chief Executive Officer of the Company and as a member of the Board, effective July 13, 2026. Following his departure, he will provide strategic advisory services under a consulting agreement until August 16, 2026. As part of his separation agreement, Dr. Hawryluk will receive severance equal to 12 months of his base salary, COBRA continuation coverage, a cash bonus, and accelerated vesting of his equity awards. Additionally, the period for exercising his vested stock options will be extended until July 13, 2027. His departure was not linked to any disputes with the Company or its auditors, ensuring a smooth transition for the new CEO.
- : SEC 8-K (8.01): On June 12, 2026, the Company announced significant findings from the Phase 2 Avail and OLE clinical trials of canvuparatide, focusing on its efficacy in treating adult patients with chronic hyperparathyroidism (HP). The trials revealed that at 12 weeks, 63% of patients on canvuparatide met the primary endpoint, significantly outperforming the placebo group. Additionally, one-year results showed that 57% of evaluable patients achieved responder status without requiring rescue therapy, demonstrating the drug's effectiveness over a prolonged period. The trials also highlighted improvements in calcium homeostasis, kidney function, and safety, confirming canvuparatide’s potential for weekly dosing with no new safety concerns arising over the treatment period.
- : SEC 8-K (5.02): On June 4, 2026, MBX Biosciences, Inc. held its 2026 annual meeting of stockholders where the election of two Class II directors, Patrick J. Heron and Edward T. Mathers, was approved by the stockholders. They will serve a three-year term ending at the annual meeting of stockholders in 2029. The total number of outstanding shares was reported as 47,570,485, with a significant majority of votes in favor of the nominees, indicating strong support. Additionally, the stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, a key decision for the Company's financial oversight and compliance.
- : SEC 8-K (8.01): On May 11, 2026, the Company provided an update regarding its obesity drug portfolio, focusing on initial results from the MBX 4291 Phase 1 clinical trial and the nomination of MBX 5765 as a development candidate. This update highlights significant aspects of the ongoing Phase 1 study design, which includes evaluations of safety, tolerability, and pharmacokinetics. Additionally, it presents compelling market statistics, noting 890 million adults living with obesity, and forecasts that the obesity drug market could exceed $90 billion by 2031. The findings from the trial indicate favorable pharmacokinetics and safety profiles for MBX 4291, suggesting potential for future monthly dosing.
- : SEC 8-K (8.01): On March 9, 2026, the Company announced the completion of an End-of-Phase 2 (EOP2) meeting with the U.S. FDA regarding its drug canvuparatide for the treatment of chronic hypoparathyroidism (HP). Based on FDA feedback, the Company plans to initiate a Phase 3 clinical trial in Q3 2026, enrolling approximately 160 patients, randomized to receive either canvuparatide or a placebo. The trial will assess the primary endpoint of achieving normal serum calcium levels and reducing dependency on conventional therapy, with significant implications for enhancing HP treatment protocols. Additionally, canvuparatide has received Orphan Drug Designation from the European Medicines Agency, further supporting its development in Europe.
- : SEC 8-K (5.02): On February 25, 2026, Richard Bartram resigned as Chief Financial Officer of the Company, entering into a separation agreement that allows him to remain employed until March 15, 2026, while also providing consulting services afterward. His departure is not due to any dispute, and he will receive continued salary payments, benefits, and severance while his equity awards will continue to vest. Additionally, John Smither has been appointed as the Interim Chief Financial Officer effective March 16, 2026, bringing over 40 years of experience in finance within the biotechnology sector. The transition reflects a strategic shift in leadership as the Company seeks a new CFO.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
MBX Biosciences, Inc. funding history
| Date | Round | Amount |
|---|---|---|
| Nov 2022 | Venture | $46.7M |
| Jul 2020 | Venture | $25.8M |
| Jul 2020 | Series A | $34.0M |
| May 2019 | Venture | $23.0M |
Leadership
- Timothy Knickerbocker, Executive Officer, Director
- Richard DiMarchi, Executive Officer, Director
- Peter Hawryluk, Executive Officer, Director
- Karen Basbaum, Chief Business Officer
- Kent Hawryluk, President
- Salomon (Sam) Azoulay, Chief Medical Officer
- Steven Prestrelski, Chief Scientific Officer
Verified email and direct lines for MBX Biosciences, Inc.’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
MBX Biosciences, Inc. files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
MBX Biosciences, Inc. in the news
- MBX Biosciences Provides Obesity Portfolio Update Including - GlobeNewswire (May 11, 2026)
- MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City - Yahoo Finance (May 26, 2026)
- MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance (Jan 11, 2026)
- MBX Biosciences to Participate in Upcoming Investor Conferences - GlobeNewswire (Sep 09, 2026)
- MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio - Yahoo Finance (Apr 23, 2026)
- MBX Biosciences Announces One-Year Data Demonstrating - GlobeNewswire (Jun 12, 2026)
- MBX Biosciences, Inc. (MBX) Stock Price, News, Quote & History - Yahoo Finance (Sep 13, 2024)
Companies similar to MBX Biosciences, Inc.
- Corvus Pharmaceuticals, Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- vTv Therapeutics Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Arbutus · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Longboard Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Savara Inc · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
About MBX Biosciences, Inc.: questions and answers
What does MBX Biosciences, Inc. do?
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company pioneering Precision Endocrine Peptide™ (PEP™) therapeutic candidates to help people with endocrine disorders live fuller and healthier lives. The company is advancing a pipeline of PEPs for clinically validated targets designed to deliver superior pharmaceutical properties and overcome key limitations of native peptide therapeuti
Where is MBX Biosciences, Inc. headquartered?
MBX Biosciences, Inc. is headquartered in Carmel, Indiana, United States.
Has MBX Biosciences, Inc. raised funding?
Yes. Fundz has recorded 4 funding events for MBX Biosciences, Inc.. The most recent, $46.7M, was in Nov 2022.
Who leads MBX Biosciences, Inc.?
Kent Hawryluk is a President at MBX Biosciences, Inc..
What is the latest news on MBX Biosciences, Inc.?
On Mar 10, 2026, MBX Biosciences Appoints Karen Basbaum as Chief Business Officer
Is MBX Biosciences, Inc. a public company?
Yes. MBX Biosciences, Inc. is publicly traded under the ticker MBX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy